Показать сокращенную информацию

dc.contributor.authorMirza, M.
dc.contributor.authorGhamande, Sh.
dc.contributor.authorHanker, L. Ch.
dc.contributor.authorBlack, D.
dc.contributor.authorRaascou-Jensen, N.
dc.contributor.authorGilbert, L.
dc.contributor.authorOaknin, A.
dc.contributor.authorSecord, A. A.
dc.contributor.authorSavarese, A.
dc.contributor.authorHolloway, R. W.
dc.contributor.authorKristeleit, R.
dc.contributor.authorBuscema, J.
dc.contributor.authorBoere, I. A.
dc.contributor.authorSharma, S.
dc.contributor.authorGennigens, Ch.
dc.contributor.authorGhatage, P.
dc.contributor.authorYablons, K.
dc.contributor.authorStevens, S.
dc.contributor.authorTrukhan, H.
dc.contributor.authorPowell, M.
dc.date.accessioned2025-03-06T07:50:15Z
dc.date.available2025-03-06T07:50:15Z
dc.date.issued2024
dc.identifier.urihttps://rep.bsmu.by/handle/BSMU/47502
dc.descriptionProgression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial / M. Mirza, Sh. Ghamande, L. Ch. Hanker [et al.] // ESMO Open. – 2024. – Vol. 9, suppl. 5. – Art. 103538. – URL: https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2824%2901307-3 (date of access: 04.03.2025).ru_RU
dc.description.abstractBackground: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pA/rEC, patients (pts) receiving dostarlimab (dostar)/carboplatin-paclitaxel (CP) exhibited significant benets in PFS and overall survival versus CP alone. Outcomes may be further improved by adding a poly(ADP-ribose) polymerase inhibitor (PARPi). Here we report results from Part 2 of RUBY of dostar/CP followed by dostar/niraparib (nira; a PARPi) maintenance therapy in pts with pA/rEC. Methods: Pts were randomized 2:1 to dostar 500 mg IV + CP Q3W for 6 cycles followed by dostar 1000 mg IV Q6W + nira (individualized starting dose of 200 or 300 mg) PO daily for 3 years from randomization or to placebo (PBO) + CP Q3W for 6 cycles followed by PBOs for 3 years. The primary endpoint was PFS in the overall and MMRp/MSS populations. Results: 291 pts were randomized (192 dostar/CP + dostar/nira; 99 PBO/CP). PFS was significantly improved in pts receiving dostar/CP + dostar/nira vs PBO/CP in the overall and MMRp/MSS populations (Table). In pts with endometrioid carcinoma, pts with other histologies, and across most biomarker subgroups (eg, TP53mut), the hazard ratio (HR) directionally favored dostar/CP + dostar/nira in the overall and MMRp/MSS populations. The safety pro fi le observed was consistent with those of the individual agents.ru_RU
dc.language.isoenru_RU
dc.titleProgression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trialru_RU
dc.typeArticleru_RU


Файлы в этом документе

Thumbnail

Данный элемент включен в следующие коллекции

Показать сокращенную информацию